Can a skin biopsy reveal how axatilimab fights scarring in chronic GVHD?
NCT ID NCT07728708
First seen Jul 27, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This study investigates how axatilimab, an FDA-approved drug for chronic graft-versus-host disease (cGVHD), changes immune cells in the skin. Researchers will analyze skin and blood samples from 15 adults with skin cGVHD—10 starting axatilimab and 5 not receiving it—to understand how the drug reduces inflammation and scarring. The goal is to uncover biological markers that could improve future treatments for cGVHD and other fibrotic diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- axatilimab
- What this could lead to
- If successful, this study could reveal how axatilimab reduces skin inflammation and scarring in chronic GVHD, potentially guiding better treatments for this condition and other scarring diseases.
- What could go wrong
- This is a small observational study with only 15 participants, so findings may not apply broadly. It does not test new treatments or directly benefit participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern Medicine
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody cocktail targets stubborn liver disease after stem cell transplants
- New drug combo aims to tame transplant complication
- New drug shows promise in controlling transplant complications
- Arthritis drug repurposed to fight stem cell transplant complication
- New combo therapy aims to tame chronic GVHD
- Simple blood test could predict transplant complications